Valneva SE (VLA.PA) stock: key figures, P/E, revenue and dividend
Health Care · France · ISIN FR0004056851
Valneva SE financials
| Fiscal year | 2024 | 2025 |
|---|---|---|
| Revenue | 169.00 m EUR | 174.00 m EUR |
| Gross profit | 71.00 m EUR | 67.00 m EUR |
| Operating income | 13.78 m EUR | -81.63 m EUR |
| EBIT | 13.00 m EUR | -81.00 m EUR |
| Net income | -12.00 m EUR | -115.00 m EUR |
| Diluted EPS – continuing operations | -0.08 EUR | -0.66 EUR |
Full history since 2004, charts and your own formulas
This page shows the last two fiscal years. After free sign-up you get the full income statement, balance sheet and cash flow, price and dividend charts, your own formula metrics and a stock screener covering more than 8,000 companies.
About Valneva SE
Valneva SE, a specialty vaccine company, develops, manufactures, and commercializes prophylactic vaccines for infectious diseases with unmet needs. It offers IXIARO, an inactivated Vero cell culture-derived Japanese encephalitis vaccine indicated for active immunization against Japanese encephalitis; DUKORAL, an oral vaccine for the prevention of diarrhea caused by Vibrio cholera or heat-labile toxin producing enterotoxigenic Escherichia coli bacterium; and IXCHIQ/ VLA1553, a single-dose, live-attenuated vaccine for the prevention of disease caused by chikungunya virus. The company also develops VLA15, a vaccine candidate against Borrelia, the bacterium that causes Lyme disease; S4V2, a tetravalent bioconjugate vaccine candidate against shigellosis, a diarrheal infection caused by Shigella bacteria; VLA1601, a vaccine candidate targeting the Zika virus, a mosquito-borne viral disease; VLA1554, a vaccine candidate targeting human metapneumovirus; VLA84, a vaccine candidate targeting the prevention of primary symptomatic clostridium difficile infection; PF-07307405, a vaccine candidate to prevent Lyme disease cases in individuals aged five years and older and VLA2112, a vaccine candidate to treat patients with epstein-barr virus. It sells its products in the United States, Canada, Germany, Austria, Nordics, the United Kingdom, France, rest of Europe, and internationally. Valneva SE was founded in 1998 and is based in Saint-Herblain, France.
More stocks
- Zhejiang Biyi Electric Appliance Co. Ltd. (603215.SS)
- Ocumension Therapeutics (1477.HK)
- Shanghai Koal Software Co Ltd (603232.SS)
- FARMERS & MERCHANTS BANCORP INC (FMAO)
- ACCO BRANDS Corp (ACCO)
- China Steel Chemical Corp (1723.TW)
- Sijin Intelligent Forming Machinery (003025.SZ)
- Tinc NV (TINC.BR)
- ZheJiang Haers Vacuum Containers Co Ltd (002615.SZ)
- Electra Therapeutics, Inc. Common stock (ETRA)
- Shanghai National Center of Testing and Inspection for Electric Cable and Wire Co. Ltd. (301289.SZ)
- ANGIODYNAMICS INC (ANGO)
Not investment advice. All data without warranty, price as of 29.10.2026. Details in the risk notice.